Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Planchard

Showing results (21-30 of 243) with videos related to

Pageof 25
Sort By:
Lung Cancer (Amsterdam, Netherlands)|June 13, 2022
Targeting BRAF-mutant non-small cell lung cancer: Current status and future directionsMariona Riudavets, Priscilla Cascetta, David Planchard
Cancer|June 1, 2026
Mapping the antibody-drug-conjugates landscape in non-small cell lung cancer: Where are we and where are we going?Claudia Parisi, Fabrice Barlesi, David Planchard
Drugs|January 31, 2026
First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?Pamela Abdayem, Claudia Parisi, David Planchard
Expert Opinion on Drug Safety|November 21, 2018
Safety of osimertinib in EGFR-mutated non-small cell lung cancerLaura Mezquita, Andreea Varga, David Planchard
Presse Medicale (Paris, France : 1983)|March 23, 2011
[Lung cancer in never smoker: Epidemiology, molecular profiles and treatment]Julien Hadoux, Benjamin Besse, David Planchard
Current Opinion in Oncology|January 13, 2016
Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancerJordi Remon, Nathalie Chaput, David Planchard
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung CancerHelena A Yu, David Planchard, Christine M Lovly
La Revue Du Praticien|March 16, 2010
[Screening and early diagnosis of other cancers (non-small cell lung carcinoma, urologic cancers, liver cancer and melanoma)]Michel Ducreux, Christine Mateus, David Planchard, et al.
Expert Opinion on Pharmacotherapy|February 17, 2021
An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an updateLuigi Cerbone, Jose Carlos Benitez, David Planchard, et al.
Critical Reviews in Oncology/Hematology|February 29, 2020
Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLCIosune Baraibar, Laura Mezquita, Ignacio Gil-Bazo, et al.
Pageof 25

Showing results (21-30 of 243) with videos related to

Sort By:
Pageof 25
Lung Cancer (Amsterdam, Netherlands)|June 13, 2022
Targeting BRAF-mutant non-small cell lung cancer: Current status and future directionsMariona Riudavets, Priscilla Cascetta, David Planchard
Cancer|June 1, 2026
Mapping the antibody-drug-conjugates landscape in non-small cell lung cancer: Where are we and where are we going?Claudia Parisi, Fabrice Barlesi, David Planchard
Drugs|January 31, 2026
First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?Pamela Abdayem, Claudia Parisi, David Planchard
Expert Opinion on Drug Safety|November 21, 2018
Safety of osimertinib in EGFR-mutated non-small cell lung cancerLaura Mezquita, Andreea Varga, David Planchard
Presse Medicale (Paris, France : 1983)|March 23, 2011
[Lung cancer in never smoker: Epidemiology, molecular profiles and treatment]Julien Hadoux, Benjamin Besse, David Planchard
Current Opinion in Oncology|January 13, 2016
Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancerJordi Remon, Nathalie Chaput, David Planchard
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung CancerHelena A Yu, David Planchard, Christine M Lovly
La Revue Du Praticien|March 16, 2010
[Screening and early diagnosis of other cancers (non-small cell lung carcinoma, urologic cancers, liver cancer and melanoma)]Michel Ducreux, Christine Mateus, David Planchard, et al.
Expert Opinion on Pharmacotherapy|February 17, 2021
An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an updateLuigi Cerbone, Jose Carlos Benitez, David Planchard, et al.
Critical Reviews in Oncology/Hematology|February 29, 2020
Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLCIosune Baraibar, Laura Mezquita, Ignacio Gil-Bazo, et al.
Pageof 25